Mnemosyne Pharmaceuticals Inc.
Selective NMDA modulators for neuropsychiatric disorders
This article was originally published in Start Up
Less than half of patients with major depressive disorder respond to current therapies; that’s why clinical studies showing that the anesthetic medication ketamine benefitted MDD patients within hours made headlines, despite ketamine’s serious drawbacks. Mnemosyne Pharmaceuticals Inc. has identified a highly selective oral compound that hits the same target as ketamine but with less of the effects that can lead to abuse.